SG&A expenses were $122.0 million for the third quarter of 2024, compared to $145.7 million for the same period in 2023. The decrease was primarily attributable to decreases in personnel related costs ...

Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy (GA), a sight-robbing condition that accompanies age-related macular degeneration (AMD ...

Izervay (avacincaptad pegol) has been cleared by the US regulator for GA secondary to age-related macular degeneration (AMD), a leading form of blindness, setting up a market clash with Apellis ...

If you're planning to upgrade your rig, now is the ideal time to look for the best AMD processor for your needs and budget. With Black Friday deals approaching, you can find some fantastic deals ...

Nov. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals ... U.S. net product revenue in the third quarter 2024. SYFOVRE commercial vials grew by approximately 7% quarter-over-quarter.

Commercial Vials Shipped: 84,500 vials of Syfovre in Q3 2024, a 7% increase from Q2 2024. Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a 7% quarter-over-quarter growth in commercial ...

Overall, Apellis reported total third-quarter revenues of $196.8 million, up 78% year over year. Beyond Syfovre, the company’s paroxysmal nocturnal hemoglobinuria drug Empaveli grew sales 0.4% ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

In closing, our strong fundamentals position us well for the future. Apellis has two commercial products, each with blockbuster potential, which are already making a meaningful difference in ...

Apellis Pharmaceuticals (NASDAQ ... However, the company said Syfovre commercial vials grew ~7% sequentially and projected a stable outlook for gross-to-net adjustments with “modest” quarterly ...